Crestor and Apixaban Interaction: What Women Need to Know

What Is the Interaction Between Crestor and Apixaban?

The short answer: rosuvastatin and apixaban share transporter pathways at the level of the intestinal wall and liver, but the clinical effect is modest in most women. Neither drug is primarily metabolized by CYP3A4 in the same direction, so the classic "CYP3A4 statin danger" that applies to simvastatin or lovastatin does not apply here. The concern is more subtle: shared P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) transport.

How Rosuvastatin Moves Through Your Body

Rosuvastatin is absorbed via the intestine and taken up into hepatocytes through OATP1B1 and OATP1B3 transporters. Inside the liver, where it does its cholesterol-lowering work, it is also a substrate of BCRP (ABCG2). It undergoes minimal CYP metabolism (roughly 10% via CYP2C9). This transporter-heavy profile means that drugs affecting BCRP or OATP1B1 can raise rosuvastatin plasma levels and increase myopathy risk, while drugs affecting P-gp can alter intestinal absorption.

How Apixaban Moves Through Your Body

Apixaban, a direct oral anticoagulant (DOAC) that inhibits factor Xa, is a substrate of both P-gp and CYP3A4. It does not meaningfully inhibit OATP1B1 or BCRP at therapeutic concentrations. Its bioavailability is approximately 50%, and its half-life is 12 hours, driving the twice-daily dosing schedule. Renal excretion accounts for about 27% of total clearance.

Where the Two Pathways Overlap

The overlap is at P-gp. Rosuvastatin is a weak P-gp substrate. If apixaban competed strongly for P-gp efflux at the intestinal level, it could theoretically raise rosuvastatin bioavailability. In practice, pharmacokinetic modeling and the FDA labels for both agents do not mandate dose adjustment for this pair. The interaction is classified as minor to moderate in clinical drug-interaction databases, with the most meaningful clinical caution being additive or pharmacodynamic bleeding risk when other anticoagulant-affecting drugs enter the picture.

A practical framework for this interaction in women:

| Factor | Clinical Weight | |---|---| | Rosuvastatin dose <20 mg | Transporter competition less relevant | | Rosuvastatin dose 40 mg | BCRP saturation possible; monitor CK if symptomatic | | Apixaban 5 mg BID (standard) | Low P-gp inhibitory effect on rosuvastatin | | Apixaban 2.5 mg BID (dose-reduced) | Seen in older women with renal impairment; lower systemic exposure | | Concurrent OATP inhibitors (cyclosporine, gemfibrozil) | Raises rosuvastatin AUC dramatically; far more important than apixaban itself | | Concurrent P-gp inhibitors (clarithromycin, ketoconazole) | Raises apixaban exposure; modify apixaban dose per FDA guidance |

Why This Interaction Matters Differently for Women

Women are not a homogeneous group, and the clinical weight of taking both a statin and a DOAC shifts across your reproductive life.

Reproductive Years (Ages 18 to 45)

In your reproductive years, the most common reasons you might be prescribed apixaban include venous thromboembolism (VTE) treatment, antiphospholipid syndrome, or atrial fibrillation (AF) related to structural heart disease. PCOS is worth naming here explicitly: women with PCOS have a significantly elevated VTE risk, partly driven by insulin resistance, obesity, and inflammatory state. If you also have dyslipidemia from PCOS (elevated triglycerides, low HDL), rosuvastatin may be prescribed alongside anticoagulation. The combination is used in this population, but long-term pharmacokinetic data specifically in women with PCOS are limited. That evidence gap is real.

Oral contraceptives (OCs) add a layer of complexity. Combined OCs that contain ethinylestradiol are themselves P-gp inducers and raise VTE risk independently. Using apixaban alongside an OC for contraception while on rosuvastatin creates a three-way interaction profile that has not been studied in a dedicated trial. If you are on apixaban for VTE treatment, most guidelines recommend against combined hormonal contraception for additional thromboprophylaxis purposes; a progestin-only pill or non-hormonal method is preferred.

Trying to Conceive or Pregnant

Stop here. Both rosuvastatin and apixaban are contraindicated in pregnancy. See the dedicated section below.

Perimenopause (Typically Ages 45 to 55)

Cardiovascular risk rises sharply in perimenopause. LDL often climbs, and AF incidence increases. The NAMS 2022 Hormone Therapy Position Statement notes that women in early menopause transition who are under 60 or within 10 years of menopause onset have a favorable cardiovascular benefit-risk profile for estrogen therapy, but this must be weighed against any concurrent anticoagulation. If you are perimenopausal, on rosuvastatin for dyslipidemia, and newly prescribed apixaban for AF, your prescriber should review your full medication list, including any hormone therapy, before confirming doses.

Menopausal hormone therapy (MHT) with oral estrogens raises SHBG and alters hepatic drug metabolism. Transdermal estradiol has a more neutral effect on coagulation compared to oral estrogen and is generally preferred when anticoagulation is also in play. This is not a reason to avoid rosuvastatin, but it is a reason to flag your MHT route to your prescriber.

Post-Menopause

Post-menopausal women are the highest-volume demographic taking both statins and DOACs simultaneously. The ARISTOTLE trial, which established apixaban's superiority over warfarin in AF, enrolled 18,201 patients but did not stratify drug-interaction subanalyses by sex or by concurrent statin use. This is the data gap women deserve to know about. Women comprised only about 35% of the ARISTOTLE population. Extrapolating the interaction data from a male-majority trial to a post-menopausal woman with different renal function, body composition, and hepatic transporter expression is a known limitation.

Pregnancy and Lactation Safety: A Required Section

This is the most absolute clinical statement in this article: do not take rosuvastatin or apixaban during pregnancy.

Rosuvastatin in Pregnancy

Rosuvastatin carries FDA Pregnancy Category X. Animal studies demonstrate fetal harm. Human data are limited but include case reports of congenital anomalies. Statins inhibit cholesterol synthesis, and cholesterol is required for fetal steroidogenesis and membrane development. The FDA label states rosuvastatin is contraindicated in pregnancy and in women who may become pregnant. You must use reliable contraception while taking rosuvastatin. If you become pregnant while taking it, stop immediately and contact your clinician.

Apixaban in Pregnancy

Apixaban has no established human pregnancy safety data. The FDA label notes that anticoagulant effects cannot be reliably monitored with standard tests and that use during pregnancy may increase bleeding risk for both the pregnant woman and the fetus. For women who require anticoagulation during pregnancy (for example, for VTE or mechanical heart valves), low-molecular-weight heparin (LMWH) such as enoxaparin is the standard of care. DOACs, including apixaban, are not approved for use in pregnancy.

Lactation

Rosuvastatin is excreted into breast milk in animal studies. The FDA label advises against breastfeeding while taking rosuvastatin. Apixaban's transfer into human breast milk has not been studied adequately. Given the potential for neonatal bleeding and the lack of human data, breastfeeding while taking apixaban is generally not recommended. If you are postpartum and need anticoagulation, speak with your clinician about transitioning to an agent with better lactation data.

Contraception Requirement

Because rosuvastatin is Category X, women of reproductive potential must use effective contraception throughout treatment. The requirement is not lifted during brief treatment gaps. A non-hormonal method or progestin-only method (particularly if you are also on apixaban, given VTE risk with combined OCs) is worth discussing with your provider.

Bleeding Risk: What the Data Actually Show

The pharmacodynamic concern with combining a statin and a DOAC is not statin-driven bleeding per se. Statins do not thin the blood. The bleeding risk comes entirely from apixaban. Adding rosuvastatin does not appear to meaningfully amplify apixaban's anticoagulant effect based on current labeling.

However, two indirect pathways deserve mention:

Statin-Induced Myopathy and Muscle Enzyme Elevation

At high rosuvastatin doses (40 mg), rare cases of rhabdomyolysis produce myoglobin that can impair renal function. Apixaban's dose-reduction criteria are triggered by serum creatinine 1.5 mg/dL or higher combined with age or weight thresholds. A rosuvastatin-induced acute kidney injury could therefore indirectly push a patient into apixaban dose-reduction territory. This is a low-probability but mechanistically coherent risk chain.

Gastrointestinal Bleeding

Apixaban, like all DOACs, carries a GI bleeding risk. The ARISTOTLE trial showed apixaban's GI bleed rate was lower than warfarin (0.76% vs. 0.86% per year), but the risk is not zero. Rosuvastatin is not known to damage the GI mucosa, so the combination does not synergistically increase GI bleeding risk beyond apixaban's baseline.

Who This Drug Combination Is Right For, and Who Should Pause

Generally Appropriate Candidates

• Post-menopausal women with established ASCVD who developed AF and need both lipid control and anticoagulation
• Women with PCOS-related dyslipidemia who had a DVT/PE event and are on temporary anticoagulation
• Women on rosuvastatin for primary prevention who are newly diagnosed with AF and started on apixaban at standard doses, with no concurrent strong P-gp inhibitors or inducers

Situations That Warrant a Medication Review Before Continuing Both Drugs

• Rosuvastatin 40 mg plus apixaban plus any OATP1B1 inhibitor (cyclosporine, gemfibrozil, rifampin): the transporter load on rosuvastatin becomes clinically significant; the rosuvastatin label caps the dose at 10 mg when combined with cyclosporine
• Any concurrent use of strong P-gp and CYP3A4 inhibitors (clarithromycin, ketoconazole, ritonavir): these raise apixaban AUC by up to 160% and require dose reduction or avoidance of apixaban
• Women with CrCl <25 mL/min: apixaban use is not studied in this range; rosuvastatin also accumulates in severe renal impairment
• Pregnancy or breastfeeding (absolute contraindication for both agents)
• Women taking combined hormonal contraception alongside apixaban: the VTE-on-VTE risk should prompt a conversation about switching to a progestin-only or non-hormonal method

Monitoring: What You and Your Clinician Should Track

No specialized monitoring protocol exists specifically for the rosuvastatin-apixaban combination because the FDA labels do not identify a clinically significant pharmacokinetic interaction between the two drugs alone. Monitoring focuses on:

For Apixaban

• Bleeding signs: unusual bruising, blood in urine or stool, prolonged bleeding from cuts, heavy menstrual periods (menorrhagia is a common and under-reported sign in premenopausal women on DOACs)
• Renal function: serum creatinine at least annually, more frequently if you are older or have diabetes or hypertension
• Medication reconciliation at every visit: P-gp and CYP3A4 inhibitors can push apixaban to supratherapeutic levels without warning

For Rosuvastatin

• Fasting lipid panel 4 to 12 weeks after starting or dose-changing, then annually once at goal per ACC/AHA guidelines
• Creatine kinase (CK) if you develop unexplained muscle pain, weakness, or brown urine; routine CK monitoring is not recommended without symptoms
• Liver function tests if you develop symptoms (jaundice, right upper quadrant pain); routine LFT monitoring is no longer standard per current guidelines

Menstrual Cycle Monitoring for Premenopausal Women

Women of reproductive age taking apixaban should track their cycle length and flow. Heavy menstrual bleeding affects up to 22% of premenopausal women on DOACs. This is dramatically under-represented in DOAC trial reporting, which rarely collected menstrual data as a primary outcome. Tranexamic acid can be used episodically for heavy flow without meaningfully affecting apixaban anticoagulation, but always discuss this with your prescriber first. Hormonal IUDs (levonorgestrel-releasing) are often recommended to reduce menstrual blood loss in women who need ongoing anticoagulation.

Drug Interactions That Matter More Than Apixaban for Rosuvastatin

Because the rosuvastatin-apixaban interaction is relatively low-severity, it is worth naming the interactions that carry far greater clinical weight for women on rosuvastatin:

• Gemfibrozil: raises rosuvastatin AUC by approximately 2-fold; combination capped at rosuvastatin 10 mg
• Cyclosporine: raises rosuvastatin AUC by up to 10-fold; rosuvastatin capped at 5 mg; relevant for women post-transplant or with lupus nephritis
• Oral contraceptives: co-administration of rosuvastatin 40 mg with an ethinylestradiol/norgestrel OC increased ethinylestradiol AUC by 26% and norgestrel AUC by 34% per the rosuvastatin FDA label; this is clinically relevant for women who rely on OCs for contraception
• Antacids containing aluminum/magnesium: reduce rosuvastatin AUC by 54%; separate dosing by at least 2 hours
• Niacin above 1 g/day: raises myopathy risk in combination with any statin

Patient Counseling: What to Tell Your Prescriber

When you are filling or refilling both medications, bring your complete medication list. Specifically flag:

1. Any new antibiotic prescription, especially macrolides (azithromycin, clarithromycin) or antifungals (fluconazole, ketoconazole), because these raise apixaban exposure
2. Any change in your hormonal contraceptive method, because estrogen-containing pills affect both VTE risk and rosuvastatin pharmacokinetics
3. Any new supplement containing St. John's Wort, which induces P-gp and CYP3A4 and can reduce apixaban efficacy by a clinically meaningful margin
4. Any planned procedure or surgery: apixaban must be held 24 to 48 hours beforehand, and rosuvastatin is typically continued perioperatively unless otherwise directed

If you notice muscle pain or weakness while on rosuvastatin, do not wait for your next scheduled visit. Myopathy progresses to rhabdomyolysis rarely but can do so quickly, and any concurrent acute illness (including severe infections) raises statin myopathy risk acutely.

The Evidence Gap Women Should Know About

The ARISTOTLE trial enrolled 18,201 participants, but women made up approximately 35% of the cohort. Drug-interaction subgroup analyses were not performed by sex. The JUPITER trial, the landmark statin primary-prevention trial that included rosuvastatin 20 mg, enrolled 17,802 participants with women comprising 38%. Neither trial reported sex-stratified pharmacokinetic interaction data.

Women generally have lower body weight, different body fat distribution, and different renal clearance trajectories with aging compared to men. These factors alter both rosuvastatin's volume of distribution and apixaban's renal elimination. Until trials are designed to test these combinations specifically in women across life stages, the guidance you receive is extrapolated from male-dominant cohorts. Naming this honestly is not a reason to avoid treatment. It is a reason to follow up with your clinician more proactively and to report any unexpected symptoms.

Discuss with your WomanRx clinician whether your rosuvastatin dose is at the lowest effective level for your LDL target, and confirm that your apixaban dose reflects your current renal function and weight, particularly if your kidney function or body composition has changed since your last review.